IP Library Granted Patent US 6,908,615
Granted Patent B1
US 6,908,615 · App. 08/913,644 · Granted Jun 21, 2005

DNA encoding human papilloma virus type 18

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,908,615
App. No.
08/913,644
Granted
Jun 21, 2005
Kind
B1
Abstract

The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.

Claims (11)

1. An essentially purified HPV18 L1 protein comprising a sequence of amino acids as set forth in SEQ ID NO:2.

2. Virus-like particles comprised of recombinant L1 protein, or recombinant L1+L2 proteins of human papillomavirus 18, wherein the L1 protein comprises a sequence of amino acids as set forth in SEQ ID NO:2 and the L2 protein comprises a sequence of amino acids as set forth in SEQ ID NO:4, wherein the recombinant L1 protein or the recombinant L1+L2 proteins are produced in yeast.

3. A method of producing the virus-like particles of claim 2 , comprising:

(a) transforming yeast with a recombinant DNA molecule encoding papillomavirus L1 protein or papillomavirus L1+L2 proteins; wherein the L1 protein comprises a sequence of amino acids as set forth in SEQ ID NO:2 and the L2 protein comprises a sequence of amino acids as set forth in SEQ ID NO:4

(b) cultivating the transformed yeast under conditions that permit expression of the recombinant DNA molecule to produce the recombinant papillomavirus protein; and

(c) isolating the recombinant papillomavirus protein to produce the virus-like particles of claim 2 .

4. Recombinant papillomavirus protein produced by the method of claim 3 .

5. A vaccine comprising the virus-like particles of claim 2 and a pharmaceutically acceptable carrier.

6. Pharmaceutical compositions comprising the virus-like particles of claim 2 and a pharmaceutically acceptable carrier.

7. A method of preventing papillomavirus infection comprising administering the vaccine of claim 5 to a host.

8. A method for inducing an immune response in an animal comprising administering the virus-like particles of claim 2 to an animal.

Assignments (2)
CHANGE OF NAME Recorded Jan 28, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023861/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2008
From: LOWE, ROBERT; COOK, JAMES C. III
To: MERCK & CO., INC.
Reel/Frame 021036/0604 →